Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland

Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland

Bibliographic Details
Main Authors:	Steven Kerr, Chris Robertson, Sam Hillman, Zoe Grange, Christopher Sullivan, Aziz Sheikh
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	The Lancet Regional Health. Europe
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666776222002290

Similar Items

Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland
by: Chris Robertson, et al.
Published: (2023-05-01)

Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland
by: Calum Macdonald, et al.
Published: (2024-06-01)

Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland
by: Macdonald, C, et al.
Published: (2024)

BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
by: Igor Rudan, et al.
Published: (2022-12-01)

Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland
by: Holly Tibble, et al.
Published: (2024-06-01)

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Colin R. Simpson, et al.
Published: (2022-08-01)

Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak
by: Wenjing Ye, et al.
Published: (2023-12-01)

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
by: Thiago Cerqueira-Silva, et al.
Published: (2023-01-01)

External validation of the QCovid 2 and 3 risk prediction algorithms for risk of COVID-19 hospitalisation and mortality in adults: a national cohort study in Scotland
by: Aziz Sheikh, et al.
Published: (2023-12-01)

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
by: Agrawal, U, et al.
Published: (2022)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
by: David N. Springer, et al.
Published: (2023-08-01)

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
by: Ross L. Cameron, et al.
Published: (2016-01-01)

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
by: Gabriel Diem, et al.
Published: (2023-10-01)

SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil
by: Karoline Rodrigues Campos, et al.
Published: (2021-10-01)

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Simpson, CR, et al.
Published: (2022)

Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand
by: Kannikar Intawong, et al.
Published: (2023-12-01)

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004
by: Macfarlane Tatania V, et al.
Published: (2008-04-01)

Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection
by: Maja Sočan, et al.
Published: (2024-02-01)

Generation Scotland: an update on Scotland’s longitudinal family health study
by: Daniel McCartney, et al.
Published: (2024-06-01)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
by: Minrun Duan, et al.
Published: (2023-12-01)

Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and WalesResearch in context
by: Stuart Bedston, et al.
Published: (2024-02-01)

Cryptosporidiosis Associated with Wildlife Center, Scotland
by: Christopher C. McGuigan, et al.
Published: (2010-05-01)

Ethnic and social inequalities in COVID-19 outcomes in Scotland: protocol for early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II)
by: Rachael Wood, et al.
Published: (2021-08-01)

Effects of Drinking-Water Filtration on Cryptosporidium Seroepidemiology, Scotland
by: Colin N. Ramsay, et al.
Published: (2014-01-01)

Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
by: Odile Launay, et al.
Published: (2025-01-01)

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant
by: Zhongcheng Zhou, et al.
Published: (2022-06-01)

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
by: Lorenza Bellusci, et al.
Published: (2022-08-01)

Cost-impact study of rotavirus vaccination programme in Scotland
by: R. Heggie, et al.
Published: (2019-06-01)

Five key recommendations for the implementation of Hospital Electronic Prescribing and Medicines Administration systems in Scotland
by: Kathrin Cresswell, et al.
Published: (2017-01-01)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
by: Hao Zhou, et al.
Published: (2022-06-01)

Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior
by: Sachiko Kodera, et al.
Published: (2022-10-01)

Collecting COVID-19 at National Museums Scotland
by: Sarah Laurenson, et al.
Published: (2020-10-01)

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
by: Suvichada Assawakosri, et al.
Published: (2024-01-01)

Prevalence and risk factors for long COVID among adults in Scotland using electronic health records: a national, retrospective, observational cohort studyResearch in context
by: Karen Jeffrey, et al.
Published: (2024-05-01)

The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis
by: David J. Pascall, et al.
Published: (2023-01-01)

Trends in Total Ankle Replacement in Scotland
by: Taegyeong T. Ha, et al.
Published: (2020-10-01)

COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
by: Hermaleigh Townsley, et al.
Published: (2024-01-01)

The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis.
by: David J Pascall, et al.
Published: (2023-01-01)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
by: Suvichada Assawakosri, et al.
Published: (2022-09-01)

Tenofovir and Severe Symptomatic Hypophosphatemia
by: Asim Kichloo MD, et al.
Published: (2019-05-01)